The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.
 
Michael Kolinsky
No Relationships to Disclose
 
Joaquin Mateo
No Relationships to Disclose
 
Semini Sumanasuriya
No Relationships to Disclose
 
Pasquale Rescigno
No Relationships to Disclose
 
Diletta Bianchini
Honoraria - Janssen
Travel, Accommodations, Expenses - Janssen
 
Zafeiris Zafeiriou
No Relationships to Disclose
 
Raquel Perez Lopez
No Relationships to Disclose
 
Nina Tunariu
No Relationships to Disclose
 
Niven Mehra
No Relationships to Disclose
 
Anuradha Jayaram
No Relationships to Disclose
 
Suzanne Carreira
No Relationships to Disclose
 
Susana Miranda
No Relationships to Disclose
 
Penelope Flohr
No Relationships to Disclose
 
Ruth Riisnaes
No Relationships to Disclose
 
Jane Goodall
No Relationships to Disclose
 
Gunther Boysen
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex